SCHEMBL4385526

SCHEMBL4385526

CC1=NOC(CON=C2CCN(S(=O)(=O)c3ccc(OC(F)(F)F)cc3)CC2)C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.40
EPHX1 P07099 2/20 0.40
PRCP P42785 2/20 0.39
HTR1A P08908 1/20 0.38
ADRA1D P25100 1/20 0.38
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C19 P33261 1/20 0.37
KDM2B Q8NHM5 1/20 0.36
LIPE Q05469 1/20 0.36
HDAC3 O15379 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC7 Q8WUI4 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC10 Q969S8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4382729 0.81 EPHX2 (0.50) EPHX2EPHX1MEN1KMT2ALIPE
SCHEMBL4380733 0.80 EPHX2 (0.47) EPHX2EPHX1MEN1KMT2ALIPE
SCHEMBL4383065 0.80 EPHX2 (0.52) EPHX2EPHX1MEN1KMT2ALIPE
SCHEMBL4388873 0.80 EPHX2 (0.46) EPHX2EPHX1MEN1KMT2AALDH1A1
SCHEMBL13589003 0.79 HTR2A (0.49) EPHX2EPHX1MEN1KMT2AKDM2B
SCHEMBL4388306 0.78 EPHX2 (0.43) EPHX2EPHX1MEN1KMT2AALDH1A1
SCHEMBL4380917 0.78 MEN1 (0.47) EPHX2EPHX1PRCPHTR1AADRA1D
SCHEMBL4378966 0.78 MEN1 (0.48) EPHX2EPHX1MEN1KMT2ALIPE
SCHEMBL4387903 0.77 TSHR (0.45) EPHX2EPHX1MEN1KMT2AALDH1A1
SCHEMBL4379475 0.77 GPR119 (0.48) EPHX2EPHX1LIPE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 EPHX2 925/4885EPHX1 1507/4885PRCP 3210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.